Market Overview

Thoratec Announces Approval for HeartMate II in Japan

Related THOR
Credit Suisse Reiterates Outperform, Raises Price Target On Thoratec On Updated LVAD Estimates
Benzinga's Volume Movers

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that the company has received approval from Japan's Ministry of Health, Labour and Welfare to market HeartMate II® ^ as a Bridge-to-Transplantation therapy for patients suffering from advanced heart failure.

Posted-In: News


Related Articles (THOR)

Around the Web, We're Loving...